Tuberculosis (TB) continues to affect millions of people and their communities in poor countries. With around 8 million new cases and up to 2 million deaths each year, TB remains one of the major diseases of poverty. The emergence of drug-resistant TB has focused attention on the limitations of current strategies for diagnosis and treatment, which have been with us for more than fifty years.

TARGETS carries out interdisciplinary research on TB to understand the epidemiology and social context of the disease, particularly in the light of HIV and poverty. The Consortium also works to understand the transmission of TB and how to interrupt it, developing and testing new diagnostic tools and approaches and explaining the immunology of tuberculosis to guide vaccine development in the future. TARGETS also carries out randomised trials of both new drugs and new approaches to their management, whilst exploring the health system interactions between TB and HIV and engaging with the health policy arena.

  • Download Targeting TB for more information about some of the RPC's partners and their research in TB

Targeting TB